Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: A post hoc analysis of Phase III and long-term extension trials
BMJ Open 2025;15:e082366 Doi: 10.1136/bmjopen-2023-082366
Strand et al. showed that TOF was efficacious across both sexes, with higher responses in males observed particularly for more stringent composite endpoints and PROs. Authors conducted a post hoc analysis of placebo-controlled RCTs to evaluate TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females.
Importantly, these findings may be influenced by the small proportion of male patients (<20% of the study population) and baseline differences in PROs across sexes, with higher HAQ-DI scores and lower FACIT-F scores observed in female versus male patients. These data may assist the clinician in determining sex-specific treatment targets for patients and may support future definition of sex-appropriate MCIDs
